In Vitro Diagnostics (IVD) Quality Control Market

In Vitro Diagnostics (IVD) Quality Control Market by Source (Plasma, Whole Blood, Urine), Technology (Immunoassay, Hematology, Microbiology, Coagulation), Manufacturer (Third party, OEM), End Users (Hospitals, Lab, Research) - Global Forecast to 2027

Report Code: MD 4180 Feb, 2023, by marketsandmarkets.com

The global IVD quality control market in terms of revenue was estimated to be worth $1.3 billion in 2022 and is poised to reach $1.6 billion by 2027, growing at a CAGR of 5.4% from 2022 to 2027. The growth of the market is primarily driven by the rising number of accredited clinical laboratories, rising geriatric population, rising demand for external quality assessment programs, increasing adoption of and POC instruments in developed regions and increasing adoption of third-party quality controls. The use of quality control products is, however, not mandatory for all clinical laboratories in many countries. The lack of regulations for these products is expected to adversely affect the market growth.

IVD Quality Control Market Trends

In Vitro Diagnostics (IVD) Quality Control Market

To know about the assumptions considered for the study, Request for Free Sample Report

IVD Quality Control Market Dynamics

Driver: Growing adoption of third-party quality controls

The IVD quality controls available in the market are manufactured by either IVD instrument manufacturers or independent manufacturers. Independent manufacturers offer two types of quality controls—instrument-specific controls and third-party controls. Among these, third-party controls offer various advantages, such as a reduced need for multiple instrument-specific controls, versatility, longer shelf-life, and utility in long-term QC monitoring.

Innovative multi-analyte, multi-instrument, third-party controls enable laboratories to ensure the accuracy and reliability of multiple testing parameters with a single control, which reduces the time and cost of QC procedures. In addition, technological advancements have resulted in the introduction of multi-analyte and multi-instrument controls, which consolidate multiple instrument-specific controls into a single product—such as Randox Laboratories’ multi-analyte Acusera infectious disease (serology) control, launched in 2019. Moreover, in third-party controls, the same control lot can be used across multiple reagent lots, allowing long-term monitoring of assay performance. Considering these advantages, the adoption of third-party quality controls is increasing in the market. In addition, many regulatory bodies, such as the Clinical and Laboratory Standards Institute (CLSI), the National Association of Testing Authorities, Australia (NATA), the College of American Pathologists (CAP), the Quality Council of India (QCI), and Clinical Laboratory Improvement Amendments (CLIA) recommend the use of third-party quality controls. This trend is expected to support market growth in the coming years.

Restraint: Unfavorable reimbursement scenario for IVD tests

In many countries globally, the reimbursement scenario for IVD tests is largely unfavorable. For instance, in 2019, the Protecting Access to Medicare Act (PAMA) announced significant changes to how Medicare pays for laboratory diagnostic tests. In 2018, reimbursement payments for almost 90% of laboratory tests were lowered. The reimbursement for a rapid molecular flu test intended for use at the point of care was decreased by 18%, from USD 117 in 2017 to USD 96 in 2019. Furthermore, according to the CMS, ~75% of tests showed reductions in the reimbursement rate from January 2017. Some of these are molecular tests, targeted NGS analysis panels of five to fifty genes, and cancer tests. These developments are expected to adversely affect the US molecular and genetic testing market, thereby hindering the growth of the market.

According to MedPAC, medical testing has seen a 40% decline in reimbursement in the past 40 years. This, along with budgetary considerations in hospitals and clinical laboratories, acts as a major obstacle for the implementation of novel diagnostic techniques in clinical laboratories, as the reimbursement for these tests is low.

Opportunity: Rising demand for multi-analyte controls is serving as opportunity in this market

Technological advancements have led to the development of a new range of multi-analyte and multi-instrument controls. These innovative controls consolidate multiple instrument-specific controls into a single control, thereby enabling clinical laboratories to cut costs and greatly reduce the time taken by QC procedures.

Multi-analyte controls in the market for immunoassay testing help laboratories perform QC tests for fifty or more parameters—including cardiac and tumor markers, hormones, therapeutic drugs, kidney functions, and vitamins—in the same serum. In addition, these controls need not be changed with reagent lots and hence support long-term QC monitoring. The increasing preference for these controls is thus expected to offer significant growth opportunities for players in the market.

Challenge: Lack of regulations for clinical laboratory accreditation in several emerging countries

There are no mandatory regulations for clinical laboratory accreditations in many emerging countries across the globe. For instance, the accreditation of clinical laboratories is not mandatory in India. To establish a new medical laboratory in the country, a ‘Shops and Establishment’ license is required. This license does not ensure the incorporation of QC procedures in the laboratory. This means the laboratory can function without any QC mechanism.

In many countries, private organizations and voluntary accreditation bodies regulate QC products. Even though there is no mandatory accreditation, the Indian government has started a voluntary accreditation program through its registered body—the National Accreditation Board for Testing and Calibration Laboratories (NABL). However, laboratories are not opting for such accreditations as this may increase investments to meet the required accreditation standards. Thus, the lack of regulations to make QC mechanisms compulsory for all diagnostic tests, along with non-compliance to existing regulations, is a major challenge to the growth of the market.

Clinical Laboratories is the fastest growing market in by end user segment of the IVD Quality Control Industry

Clinical Laboratories is the fastest growing market in by end user segment of the global IVD Quality Control Market. These independent private laboratories conduct complex and specialized tests on samples received for analysis from various small/large hospitals, private practitioners, clinical research sites, and insurance companies. Reference laboratories are equipped with advanced technologies and can carry out more than 80,000 tests daily with higher turnaround times. These laboratories offer various advantages over small- and medium-sized laboratories and hospital laboratories in terms of better and more specialized testing capabilities. The increasing burden of infectious diseases across the globe, which demands larger testing volume capacities, and the growing volume of genetic testing are the key factors driving the growth of this end-user segment. Validated and accurate laboratory testing for SARS-CoV-2 is an important aspect of the timely management of COVID-19, supporting the clinical decision-making process for infection control at the healthcare level and discovering asymptomatic cases.

Independent Controls sub-segment is the fastest growing market in by manufcaturer segment of the IVD Quality Control Industry

The independent controls segment accounted for the largest share of the IVD Quality Control Market in 2021. This segment is projected to have highest CAGR during the forecast period. The high growth of this segment is mainly attributed to the fact that regulatory bodies recommend these controls. Laboratories recommend the use of third-party controls over those offered by instrument or reagent manufacturers to gain unbiased quality inputs and results. Independent controls help minimize erroneous results reporting and excessive repetition of analytical runs, which reduces costs. The use of independent controls has been seen in the manufacturing of vaccines worldwide amidst the global COVID-19 pandemic. As a condition for regulatory clearance, vaccine manufacturers must conduct a wide range of quality and safety tests on the components used in manufacturing and the final manufactured vaccines, under the scrutiny of regulatory bodies in their respective countries.

Coagulation & Hemostasis sub-segment in by Technology segment of the IVD Quality Control Industry Is growing market during the forecast period

Blood coagulation disorders include disorders arising due to the deficiency of blood coagulation factors, such as prothrombin, fibrinogen, calcium factor, and antihemophilic factors. Specific tests are required to diagnose and treat these disorders. Coagulation analyzers and reagents are used to evaluate the coagulation profile of blood samples. They are utilized for clotting-based or chromogenic assays and for diagnosing clotting factor deficiency.

Various tests are performed in coagulation laboratories for the correct diagnosis and safe management of patients with bleeding and thrombotic disorders. A laboratory error may lead to misdiagnosis, resulting in adverse clinical effects. Therefore, adequate quality control procedures are required to ensure accurate and precise patient test results.

The coagulation and hemostasis segment will be a growing market with 4.5% CAGR in the forecasted period

North America is expected to account for the largest share of the IVD quality control Industry in 2021

In Vitro Diagnostics (IVD) Quality Control Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the market include Bio-Rad Laboratories, Inc. (US), Randox Laboratories Ltd. (UK), Thermo Fisher Scientific, Inc. (US), LGC Limited (UK), and Abbott Laboratories (US). Other prominent payers in the market include Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Fortress Diagnostics (UK), SERO AS (US), Sysmex Corporation (Japan), Ortho-Clinical Diagnostics (US), Helena Laboratories Corporation (US), Quidel Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix Corporation (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics (US), Microbix Biosystems (Canada), Streck, Inc. (US), Alpha-Tec Systems (US), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).

Scope of the IVD Quality Control Industry

Report Metric

Details

Market Revenue in 2022

$1.3 billion

Estimated Value by 2027

$1.6 billion

Revenue Rate

Poised to grow at a CAGR of 5.4%

Market Driver

Growing adoption of third-party quality controls

Market Opportunity

Rising demand for multi-analyte controls is serving as opportunity in this market

The study categorizes the global IVD quality control market to forecast revenue and analyze trends in each of the following submarkets:

By Product and Service

  • Quality control products
    • Serum/ Plasma based controls
    • Whole blood based controls
    • Urine based controls
    • Other controls
  • Data Management Solutions
  • Quality Assurance Services

By Technology

  • Immunochemistry
  • Clinical Chemistry
  • Molecular Diagnostics
  • Microbiology
  • Hematology
  • Coagulation/ Hemostasis
  • Other Technologies

By Manufacturer Type

  • Third-party controls
    • Independent controls
    • Instrument specific controls
  • Original Equipment Manufacturer controls

By End User

  • Hospitals
  • Clinical Laboratories
  • Academic and Research Institutes
  • Other End users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments of IVD Quality Control Industry

  • In November 2022, Bio Rad Laboratories, Inc. made an agreement with  Abbott Laboratories (US), to expand their portfolio of independent quality controls (QC) products, including Inteliq and liquichek compact vials, for the Abbott alinity ci-series integrated clinical chemistry and immunoassay testing instruments
  • In October 2022, Thermo Fisher Scientific, Inc. (US) acquired The Binding Site Group (UK). The acquisition will enhance the specialty diagnostic segment of Thermo Fisher Scientific.
  • In August 2021, Zeptometrix Corporation (US) announced the immediate availability of its ready-to-use NATSARS(COV2)-ERC for laboratory QC and test validation
  • In July 2021, Quidel Corporation (US) received the CE Mark for its innovative Savanna multiplex molecular analyzer and Savanna RVP4 Assay (Respiratory Viral Panel-4).

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 26)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
           1.2.3 YEARS CONSIDERED
    1.3 CURRENCY 
          TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
           1.5.1 REFINEMENTS IN SEGMENTS OF GLOBAL IVD QUALITY CONTROL MARKET
           1.5.2 UPDATED FINANCIAL INFORMATION/PRODUCT PORTFOLIOS OF PLAYERS
           1.5.3 UPDATED MARKET DEVELOPMENTS OF PROFILED PLAYERS
           1.5.4 ADDITION OF RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 32)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    2.1.2.1 Primary sources
                    2.1.2.2 Key data from primary sources
                    2.1.2.3 Key industry insights
                                FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: BIO-RAD LABORATORIES, INC.
          FIGURE 6 REVENUE ANALYSIS OF TOP FIVE COMPANIES: IVD QUALITY CONTROLS MARKET (2021)
          FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF IVD QUALITY CONTROLS MARKET (2022–2027)
          FIGURE 8 CAGR PROJECTIONS
          FIGURE 9 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 MARKET DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
          TABLE 2 RISK ASSESSMENT: IVD QUALITY CONTROLS MARKET
    2.7 LIMITATIONS 
           2.7.1 METHODOLOGY-RELATED LIMITATIONS
           2.7.2 SCOPE-RELATED LIMITATIONS
    2.8 IMPACT OF RECESSION 
 
3 EXECUTIVE SUMMARY (Page No. - 45)
    FIGURE 11 IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2022 VS. 2027 (USD MILLION)
    FIGURE 12 IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 13 IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 14 THIRD-PARTY CONTROLS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    FIGURE 15 IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    FIGURE 16 IVD QUALITY CONTROLS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    FIGURE 17 GEOGRAPHICAL SNAPSHOT OF IVD QUALITY CONTROLS MARKET
 
4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 IVD QUALITY CONTROL MARKET OVERVIEW 
          FIGURE 18 GROWING ADOPTION OF THIRD-PARTY CONTROLS AND INCREASING DEMAND FOR EXTERNAL QUALITY ASSESSMENT TO DRIVE MARKET
    4.2 ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY AND COUNTRY (2021) 
          FIGURE 19 IMMUNOCHEMISTRY SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
    4.3 IVD QUALITY CONTROLS MARKET: REGIONAL MIX (2022–2027) 
          FIGURE 20 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 IVD QUALITY CONTROLS MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH FROM 2022 TO 2027
    4.5 IVD QUALITY CONTROLS MARKET: GEOGRAPHIC MIX 
          FIGURE 22 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 23 IVD QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Increasing number of accredited clinical laboratories
                                FIGURE 24 NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (2022)
                    5.2.1.2 Growing adoption of third-party quality controls
                    5.2.1.3 Rising demand for external quality assessment support
                    5.2.1.4 Rising geriatric population and subsequent growth in prevalence of chronic and infectious diseases
                                TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION (2019–2050)
                                FIGURE 25 ESTIMATED DIABETIC POPULATION, BY REGION, 2021 VS. 2030 VS. 2045 (MILLION)
                                FIGURE 26 GLOBAL CANCER INCIDENCE, 2018–2040 (MILLION)
                    5.2.1.5 Increasing adoption of POC instruments in developed regions
                                TABLE 4 MARKET DRIVERS: IMPACT ANALYSIS
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Additional costs and budget constraints in hospitals and laboratories
                    5.2.2.2 Unfavorable reimbursement scenario for IVD tests
                                TABLE 5 MARKET RESTRAINTS: IMPACT ANALYSIS
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Rising demand for multianalyte controls
                                TABLE 6 MARKET OPPORTUNITIES: IMPACT ANALYSIS
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Stringent product approval process
                    5.2.4.2 Lack of regulations for clinical laboratory accreditation in several emerging countries
                                TABLE 7 MARKET CHALLENGES: IMPACT ANALYSIS
    5.3 INDUSTRY TRENDS 
           5.3.1 LYOPHILIZED/FREEZE-DRIED CONTROLS
                    TABLE 8 LYOPHILIZED OR FREEZE-DRIED QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
           5.3.2 TRENDS ON ANALYTE SOURCE: HUMAN VS. ANIMAL ORIGIN
           5.3.3 CONSOLIDATION OF LABORATORIES
    5.4 VALUE CHAIN ANALYSIS 
          FIGURE 27 IVD QUALITY CONTROLS MARKET: VALUE CHAIN ANALYSIS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 28 IVD QUALITY CONTROLS MARKET: SUPPLY CHAIN ANALYSIS
    5.6 ECOSYSTEM MARKET MAP 
          FIGURE 29 IVD QUALITY CONTROLS MARKET: ECOSYSTEM MARKET MAP
    5.7 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 9 PORTER’S FIVE FORCES ANALYSIS
           5.7.1 INTENSITY OF COMPETITIVE RIVALRY
           5.7.2 BARGAINING POWER OF SUPPLIERS
           5.7.3 BARGAINING POWER OF BUYERS
           5.7.4 THREAT OF SUBSTITUTES
           5.7.5 THREAT OF NEW ENTRANTS
    5.8 REGULATORY ANALYSIS 
           5.8.1 NORTH AMERICA
                    5.8.1.1 US
                                TABLE 10 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL
                                TABLE 11 US: TIME, COST, AND COMPLEXITY OF REGISTRATION
                    5.8.1.2 Canada
                                TABLE 12 CANADA: CLASSIFICATION OF IVD PRODUCTS
                                TABLE 13 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION
           5.8.2 EUROPE
                    TABLE 14 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
                    TABLE 15 EUROPE: TIME, COST, AND COMPLEXITY OF REGISTRATION
           5.8.3 ASIA PACIFIC
                    5.8.3.1 Japan
                                TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION
                    5.8.3.2 China
                                TABLE 17 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION
                    5.8.3.3 India
                                TABLE 18 INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION
    5.9 PATENT ANALYSIS 
           5.9.1 PATENT PUBLICATION TRENDS FOR IVD QUALITY CONTROLS
                    FIGURE 30 PATENT PUBLICATION TRENDS (2012–2022)
           5.9.2 TOP APPLICANTS (COMPANIES) FOR PATENTS RELATED TO IVD QUALITY CONTROL
                    FIGURE 31 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR IVD QUALITY CONTROL PATENTS (2012–2022)
           5.9.3 JURISDICTION ANALYSIS: TOP APPLICANT (COUNTRIES/REGIONS) FOR PATENTS IN IVD QUALITY CONTROLS MARKET
                    FIGURE 32 JURISDICTION ANALYSIS: TOP APPLICANT (COUNTRIES/REGIONS) FOR PATENTS IN IVD QUALITY CONTROL (2012–2022)
    5.10 TECHNOLOGY ANALYSIS 
           5.10.1 KEY TECHNOLOGIES
                    5.10.1.1 Analyte extraction
                               5.10.1.1.1 Specimen pooling
                               5.10.1.1.2 Human monoclonals
                    5.10.1.2 Specimen processing
                               5.10.1.2.1 Inactivation
                               5.10.1.2.2 Dilution
                    5.10.1.3 Preservation
           5.10.2 ADJACENT TECHNOLOGIES
                    5.10.2.1 Sensor-based quality control
           5.10.3 COMPLEMENTARY TECHNOLOGIES
                    5.10.3.1 Storage
                    5.10.3.2 Transport
                    5.10.3.3 Temperature control
                    5.10.3.4 Temperature monitoring
 
6 IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE (Page No. - 81)
    6.1 INTRODUCTION 
          TABLE 19 IVD QUALITY CONTROLS MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
    6.2 QUALITY CONTROL PRODUCTS 
          TABLE 20 IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 21 IVD QUALITY CONTROL PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.1 SERUM/PLASMA-BASED CONTROLS
                    6.2.1.1 Greater stability and accuracy of diagnostic test results to increase demand for serum/plasma-based controls
                                TABLE 22 SERUM/PLASMA-BASED QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
                                TABLE 23 SERUM/PLASMA-BASED QUALITY CONTROL PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.2 WHOLE BLOOD-BASED CONTROLS
                    6.2.2.1 Rising need to ensure high-quality clinical test results to drive market
                                TABLE 24 WHOLE BLOOD-BASED QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
                                TABLE 25 WHOLE BLOOD-BASED QUALITY CONTROL PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.3 URINE-BASED CONTROLS
                    6.2.3.1 Growing incidence of kidney diseases to drive demand for urine-based controls
                                TABLE 26 URINE-BASED IVD CONTROLS OFFERED BY KEY MARKET PLAYERS
                                TABLE 27 URINE-BASED QUALITY CONTROL PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           6.2.4 OTHER CONTROLS
                    TABLE 28 OTHER CONTROLS OFFERED BY KEY MARKET PLAYERS
                    TABLE 29 OTHER QUALITY CONTROL PRODUCTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.3 DATA MANAGEMENT SOLUTIONS 
           6.3.1 RISING FOCUS ON IMPROVING ANALYTICAL PERFORMANCE OF CLINICAL LABORATORIES TO SUPPORT MARKET GROWTH
                    TABLE 30 DATA MANAGEMENT SOLUTIONS OFFERED BY KEY MARKET PLAYERS
                    TABLE 31 IVD DATA MANAGEMENT SOLUTIONS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    6.4 QUALITY ASSURANCE SERVICES 
           6.4.1 GROWING NEED FOR PERFORMANCE ASSESSMENT OF CLINICAL LABORATORIES TO INCREASE DEMAND FOR QUALITY ASSURANCE SERVICES
                    TABLE 32 QUALITY ASSURANCE SERVICES OFFERED BY KEY MARKET PLAYERS
                    TABLE 33 IVD QUALITY ASSURANCE SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
7 IVD QUALITY CONTROL MARKET, BY TECHNOLOGY (Page No. - 96)
    7.1 INTRODUCTION 
          TABLE 34 IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
    7.2 IMMUNOCHEMISTRY 
           7.2.1 FOCUS ON MONITORING PRECISION OF IMMUNOASSAY TESTS TO DRIVE ADOPTION OF IMMUNOASSAY CONTROLS
                    TABLE 35 QUALITY CONTROLS FOR IMMUNOCHEMISTRY OFFERED BY KEY MARKET PLAYERS
                    TABLE 36 IVD QUALITY CONTROLS MARKET FOR IMMUNOCHEMISTRY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.3 CLINICAL CHEMISTRY 
           7.3.1 RISING INCIDENCE OF LIFESTYLE DISEASES PROVIDES OPPORTUNITIES FOR MARKET GROWTH
                    TABLE 37 QUALITY CONTROLS FOR CLINICAL CHEMISTRY OFFERED BY KEY MARKET PLAYERS
                    TABLE 38 IVD QUALITY CONTROLS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.4 MOLECULAR DIAGNOSTICS 
           7.4.1 GROWING INCIDENCE OF INFECTIOUS DISEASES TO DRIVE DEMAND FOR MOLECULAR DIAGNOSTIC CONTROLS
                    TABLE 39 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS
                    TABLE 40 IVD QUALITY CONTROLS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.5 MICROBIOLOGY 
           7.5.1 INCREASING ADOPTION OF AUTOMATED CLINICAL MICROBIOLOGY TESTING INSTRUMENTS TO SUPPORT MARKET GROWTH
                    TABLE 41 QUALITY CONTROLS FOR MICROBIOLOGY OFFERED BY KEY MARKET PLAYERS
                    TABLE 42 IVD QUALITY CONTROLS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.6 HEMATOLOGY 
           7.6.1 NEED FOR ACCURACY IN HEMATOLOGICAL TEST RESULTS TO DRIVE RELIANCE ON HEMATOLOGY QUALITY CONTROLS
                    TABLE 43 QUALITY CONTROLS FOR HEMATOLOGY OFFERED BY KEY MARKET PLAYERS
                    TABLE 44 IVD QUALITY CONTROLS MARKET FOR HEMATOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
    7.7 COAGULATION AND HEMOSTASIS 
           7.7.1 GROWING NUMBER OF CARDIOVASCULAR SURGERIES TO DRIVE DEMAND FOR COAGULATION AND HEMOSTASIS TESTING
                    TABLE 45 QUALITY CONTROLS FOR COAGULATION AND HEMOSTASIS OFFERED BY KEY MARKET PLAYERS
                    TABLE 46 IVD QUALITY CONTROLS MARKET FOR COAGULATION AND HEMOSTASIS, BY COUNTRY, 2020–2027 (USD MILLION)
    7.8 OTHER TECHNOLOGIES 
          TABLE 47 QUALITY CONTROLS FOR OTHER TECHNOLOGIES OFFERED BY KEY MARKET PLAYERS
          TABLE 48 IVD QUALITY CONTROLS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
 
8 IVD QUALITY CONTROL MARKET, BY MANUFACTURER TYPE (Page No. - 112)
    8.1 INTRODUCTION 
          TABLE 49 IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
    8.2 THIRD-PARTY CONTROLS 
          TABLE 50 IVD THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
          TABLE 51 IVD THIRD-PARTY CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.1 INDEPENDENT CONTROLS
                    8.2.1.1 Provide unbiased and independent performance assessment for analytical processes
                                TABLE 52 INDEPENDENT CONTROLS OFFERED BY KEY MARKET PLAYERS
                                TABLE 53 INDEPENDENT THIRD-PARTY CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
           8.2.2 INSTRUMENT-SPECIFIC CONTROLS
                    8.2.2.1 Designed to evaluate and monitor performance of instruments
                                TABLE 54 INSTRUMENT-SPECIFIC CONTROLS OFFERED BY KEY MARKET PLAYERS
                                TABLE 55 INSTRUMENT-SPECIFIC THIRD-PARTY CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
    8.3 ORIGINAL EQUIPMENT MANUFACTURER CONTROLS 
           8.3.1 OEM CONTROLS TO WITNESS LOWER ADOPTION AS THEY ARE LESS SENSITIVE TO QC-RELATED ISSUES
                    TABLE 56 OEM CONTROLS OFFERED BY KEY MARKET PLAYERS
                    TABLE 57 IVD OEM CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
 
9 IVD QUALITY CONTROL MARKET, BY END USER (Page No. - 121)
    9.1 INTRODUCTION 
          TABLE 58 IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
    9.2 HOSPITALS 
           9.2.1 LARGE VOLUME OF IVD PROCEDURES PERFORMED TO DRIVE MARKET
                    TABLE 59 IVD QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION)
    9.3 CLINICAL LABORATORIES 
           9.3.1 GROWING NUMBER OF ACCREDITED LABORATORIES TO DRIVE MARKET
                    TABLE 60 IVD QUALITY CONTROLS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.4 ACADEMIC AND RESEARCH INSTITUTES 
           9.4.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO SUPPORT MARKET GROWTH
                    TABLE 61 IVD QUALITY CONTROLS MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 62 IVD QUALITY CONTROLS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION)
 
10 IVD QUALITY CONTROL MARKET, BY REGION (Page No. - 128)
     10.1 INTRODUCTION 
             TABLE 63 IVD QUALITY CONTROLS MARKET, BY REGION, 2020–2027 (USD MILLION)
             TABLE 64 IVD QUALITY CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 33 NORTH AMERICA: IVD QUALITY CONTROL MARKET SNAPSHOT
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        TABLE 65 NORTH AMERICA: IVD QUALITY CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 66 NORTH AMERICA: IVD QUALITY CONTROLS MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 67 NORTH AMERICA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 68 NORTH AMERICA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 69 NORTH AMERICA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 70 NORTH AMERICA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 71 NORTH AMERICA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.2 US
                        10.2.2.1 High healthcare expenditure to propel market growth
                                      TABLE 72 US: KEY MACROINDICATORS
                                      TABLE 73 US: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 74 US: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 75 US: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 76 US: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 77 US: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 78 US: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Government initiatives to support market growth
                                      TABLE 79 CANADA: KEY MACROINDICATORS
                                      TABLE 80 CANADA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 81 CANADA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 82 CANADA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 83 CANADA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 84 CANADA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 85 CANADA: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 86 EUROPE: IVD QUALITY CONTROL MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 87 EUROPE: IVD QUALITY CONTROLS MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 88 EUROPE: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 89 EUROPE: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 90 EUROPE: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 91 EUROPE: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 92 EUROPE: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Rising volume of high-quality tests performed to support market growth
                                      TABLE 93 GERMANY: KEY MACROINDICATORS
                                      TABLE 94 GERMANY: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 95 GERMANY: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 96 GERMANY: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 97 GERMANY: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 98 GERMANY: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 99 GERMANY: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Increasing prevalence of infectious diseases and growing demand for early diagnosis to drive market
                                      TABLE 100 FRANCE: KEY MACROINDICATORS
                                      TABLE 101 FRANCE: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 102 FRANCE: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 103 FRANCE: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 104 FRANCE: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 105 FRANCE: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 106 FRANCE: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
             10.3.4 UK
                        10.3.4.1 Growth in life sciences industry and increasing research to drive market
                                      TABLE 107 UK: KEY MACROINDICATORS
                                      TABLE 108 UK: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 109 UK: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 110 UK: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 111 UK: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 112 UK: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 113 UK: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Growing disease prevalence to drive demand for better and more accurate disease diagnosis
                                      TABLE 114 ITALY: KEY MACROINDICATORS
                                      TABLE 115 ITALY: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 116 ITALY: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 117 ITALY: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 118 ITALY: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 119 ITALY: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 120 ITALY: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Increasing demand for prenatal and genetic testing and rising focus on laboratory consolidation to support market growth
                                      TABLE 121 SPAIN: KEY MACROINDICATORS
                                      TABLE 122 SPAIN: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 123 SPAIN: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 124 SPAIN: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 125 SPAIN: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 126 SPAIN: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 127 SPAIN: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
             10.3.7 RUSSIA
                        10.3.7.1 Increasing access to quality healthcare and growing incidence of lifestyle and infectious diseases to drive market
                                      TABLE 128 RUSSIA: KEY MACROINDICATORS
                                      TABLE 129 RUSSIA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 130 RUSSIA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 131 RUSSIA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 132 RUSSIA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 133 RUSSIA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 134 RUSSIA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.3.8 REST OF EUROPE
                        TABLE 135 REST OF EUROPE: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 136 REST OF EUROPE: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 137 REST OF EUROPE: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 138 REST OF EUROPE: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 139 REST OF EUROPE: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 140 REST OF EUROPE: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 34 ASIA PACIFIC: IVD QUALITY CONTROL MARKET SNAPSHOT
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 141 ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 142 ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 143 ASIA PACIFIC: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 144 ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 145 ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 146 ASIA PACIFIC: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 147 ASIA PACIFIC: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Well-developed healthcare system and demand for improvements in quality of IVD test results to drive market
                                      TABLE 148 JAPAN: KEY MACROINDICATORS
                                      TABLE 149 JAPAN: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 150 JAPAN: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 151 JAPAN: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 152 JAPAN: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 153 JAPAN: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 154 JAPAN: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Growing access to modern healthcare and government support to boost market growth
                                      TABLE 155 CHINA: KEY MACROINDICATORS
                                      TABLE 156 CHINA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 157 CHINA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 158 CHINA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 159 CHINA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 160 CHINA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 161 CHINA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Rising need to secure NABL accreditations to drive demand for quality controls
                                      FIGURE 35 INDIA: INCREASING NUMBER OF LABORATORIES WITH NABL ACCREDITATIONS, 2012–2022
                                      TABLE 162 INDIA: KEY MACROINDICATORS
                                      TABLE 163 INDIA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 164 INDIA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 165 INDIA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 166 INDIA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 167 INDIA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 168 INDIA: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 Initiatives to enhance access to healthcare and improve infrastructure to propel market growth
                                      TABLE 169 AUSTRALIA: KEY MACROINDICATORS
                                      TABLE 170 AUSTRALIA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 171 AUSTRALIA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 172 AUSTRALIA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 173 AUSTRALIA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 174 AUSTRALIA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 175 AUSTRALIA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.6 SOUTH KOREA
                        10.4.6.1 Rising healthcare expenditure and growing number of hospitals to drive market
                                      TABLE 176 SOUTH KOREA: KEY MACROINDICATORS
                                      TABLE 177 SOUTH KOREA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 178 SOUTH KOREA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 179 SOUTH KOREA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 180 SOUTH KOREA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 181 SOUTH KOREA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 182 SOUTH KOREA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 183 REST OF ASIA PACIFIC: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 184 REST OF ASIA PACIFIC: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 185 REST OF ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 186 REST OF ASIA PACIFIC: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 187 REST OF ASIA PACIFIC: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 188 REST OF ASIA PACIFIC: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 189 LATIN AMERICA: IVD QUALITY CONTROL MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
                        TABLE 190 LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 191 LATIN AMERICA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 192 LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 193 LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 194 LATIN AMERICA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 195 LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Brazil dominates Latin American IVD quality controls market
                                      TABLE 196 BRAZIL: KEY MACROINDICATORS
                                      TABLE 197 BRAZIL: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 198 BRAZIL: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 199 BRAZIL: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 200 BRAZIL: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 201 BRAZIL: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 202 BRAZIL: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Increasing number of accredited clinical laboratories to support market growth
                                      TABLE 203 MEXICO: KEY MACROINDICATORS
                                      TABLE 204 MEXICO: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                                      TABLE 205 MEXICO: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 206 MEXICO: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                                      TABLE 207 MEXICO: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                                      TABLE 208 MEXICO: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                                      TABLE 209 MEXICO: IVD QUALITY CONTROL INDUSTRY, BY END USER, 2020–2027 (USD MILLION)
             10.5.4 REST OF LATIN AMERICA
                        TABLE 210 REST OF LATIN AMERICA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 211 REST OF LATIN AMERICA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 212 REST OF LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 213 REST OF LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 214 REST OF LATIN AMERICA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 215 REST OF LATIN AMERICA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
     10.6 MIDDLE EAST AND AFRICA 
             10.6.1 MIDDLE EAST AND AFRICA: RECESSION IMPACT
             10.6.2 RISING CANCER INCIDENCE TO DRIVE MARKET
                        TABLE 216 MIDDLE EAST AND AFRICA: IVD QUALITY CONTROL MARKET, BY PRODUCT AND SERVICE, 2020–2027 (USD MILLION)
                        TABLE 217 MIDDLE EAST AND AFRICA: IVD QUALITY CONTROL PRODUCTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 218 MIDDLE EAST AND AFRICA: IVD QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
                        TABLE 219 MIDDLE EAST AND AFRICA: IVD QUALITY CONTROLS MARKET, BY MANUFACTURER TYPE, 2020–2027 (USD MILLION)
                        TABLE 220 MIDDLE EAST AND AFRICA: THIRD-PARTY CONTROLS MARKET, BY TYPE, 2020–2027 (USD MILLION)
                        TABLE 221 MIDDLE EAST AND AFRICA: IVD QUALITY CONTROLS MARKET, BY END USER, 2020–2027 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 199)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
     11.3 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS 
             FIGURE 36 REVENUE ANALYSIS OF TOP PLAYERS IN IVD QUALITY CONTROL MARKET
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 37 IVD QUALITY CONTROLS MARKET SHARE, BY KEY PLAYER, 2021
     11.5 COMPETITIVE BENCHMARKING 
             TABLE 222 PRODUCT PORTFOLIO ANALYSIS: IVD QUALITY CONTROLS MARKET
             TABLE 223 TECHNOLOGY PORTFOLIO ANALYSIS: IVD QUALITY CONTROLS MARKET
             TABLE 224 MANUFACTURER TYPE PORTFOLIO ANALYSIS: IVD QUALITY CONTROLS MARKET
             TABLE 225 END-USER PORTFOLIO ANALYSIS: IVD QUALITY CONTROLS MARKET
     11.6 REGIONAL FOOTPRINT OF KEY PLAYERS 
             TABLE 226 REGIONAL REVENUE MIX: IVD QUALITY CONTROLS MARKET
     11.7 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS 
             11.7.1 STARS
             11.7.2 EMERGING LEADERS
             11.7.3 PERVASIVE PLAYERS
             11.7.4 PARTICIPANTS
                        FIGURE 38 IVD QUALITY CONTROLS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS (2021)
     11.8 R&D EXPENDITURE 
             FIGURE 39 IVD QUALITY CONTROLS MARKET: R&D EXPENDITURE (USD MILLION), 2021
     11.9 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 
             11.9.1 PROGRESSIVE COMPANIES
             11.9.2 DYNAMIC COMPANIES
             11.9.3 STARTING BLOCKS
             11.9.4 RESPONSIVE COMPANIES
                        FIGURE 40 IVD QUALITY CONTROL MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2021)
     11.1 COMPETITIVE SITUATIONS AND TRENDS 
             11.10.1 DEALS
                        TABLE 227 DEALS, JANUARY 2019–JANUARY 2023
             11.10.2 PRODUCT LAUNCHES
                        TABLE 228 PRODUCT LAUNCHES, JANUARY 2019–JANUARY 2023
             11.10.3 OTHER DEVELOPMENTS
                        TABLE 229 OTHER DEVELOPMENTS, JANUARY 2019–JANUARY 2023
 
12 COMPANY PROFILES (Page No. - 216)
(Business overview, Products and services offered, Recent developments & MnM View)*
     12.1 KEY PLAYERS 
             12.1.1 BIO-RAD LABORATORIES, INC.
                        TABLE 230 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 41 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
             12.1.2 THERMO FISHER SCIENTIFIC, INC.
                        TABLE 231 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
                        FIGURE 42 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
             12.1.3 RANDOX LABORATORIES LTD.
                        TABLE 232 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
             12.1.4 LGC LIMITED
                        TABLE 233 LGC LIMITED: BUSINESS OVERVIEW
                        FIGURE 43 LGC LIMITED: COMPANY SNAPSHOT (2021)
             12.1.5 ROCHE DIAGNOSTICS
                        TABLE 234 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 44 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021)
             12.1.6 ABBOTT LABORATORIES
                        TABLE 235 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 45 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.7 SIEMENS HEALTHINEERS
                        TABLE 236 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW
                        FIGURE 46 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2021)
             12.1.8 QUIDEL CORPORATION
                        TABLE 237 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.9 DANAHER CORPORATION
                        TABLE 238 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.10 SYSMEX CORPORATION
                        TABLE 239 SYSMEX CORPORATION: BUSINESS OVERVIEW
                        FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.11 ORTHO-CLINICAL DIAGNOSTICS, INC.
                        TABLE 240 ORTHO-CLINICAL DIAGNOSTICS, INC.: BUSINESS OVERVIEW
                        FIGURE 50 ORTHO-CLINICAL DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2021)
             12.1.12 BIO-TECHNE CORPORATION
                        TABLE 241 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 51 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)
             12.1.13 SEEGENE INC.
                        TABLE 242 SEEGENE INC.: BUSINESS OVERVIEW
                        FIGURE 52 SEEGENE INC.: COMPANY SNAPSHOT (2020)
             12.1.14 QNOSTICS
                        TABLE 243 QNOSTICS: BUSINESS OVERVIEW
             12.1.15 MICROBIOLOGICS, INC.
                        TABLE 244 MICROBIOLOGICS: BUSINESS OVERVIEW
             12.1.16 ZEPTOMETRIX CORPORATION
                        TABLE 245 ZEPTOMETRIX CORPORATION: BUSINESS OVERVIEW
             12.1.17 FORTRESS DIAGNOSTICS
                        TABLE 246 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW
             12.1.18 MICROBIX BIOSYSTEMS INC.
                        TABLE 247 MICROBIX BIOSYSTEMS INC.: BUSINESS OVERVIEW
                        FIGURE 53 MICROBIX BIOSYSTEMS, INC.: COMPANY SNAPSHOT (2021)
             12.1.19 GRIFOLS, S.A.
                        TABLE 248 GRIFOLS, S.A.: BUSINESS OVERVIEW
                                                FIGURE 54 GRIFOLS, S.A.: COMPANY SNAPSHOT (2021)
             12.1.20 ALPHA-TEC SYSTEMS, INC.
                        TABLE 249 ALPHA-TEC SYSTEMS, INC.: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 HELENA LABORATORIES CORPORATION
                        TABLE 250 HELENA LABORATORIES CORPORATION: BUSINESS OVERVIEW
             12.2.2 STRECK, INC.
                        TABLE 251 STRECK, INC.: BUSINESS OVERVIEW
             12.2.3 MAINE MOLECULAR QUALITY CONTROLS, INC.
                        TABLE 252 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW
             12.2.4 SUN DIAGNOSTICS, LLC
                        TABLE 253 SUN DIAGNOSTICS, LLC: BUSINESS OVERVIEW
             12.2.5 SERO AS
                        TABLE 254 SERO AS: BUSINESS OVERVIEW
 
*Details on Business overview, Products and services offered, Recent developments & MnM View might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 323)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This study involved the extensive use of both primary and secondary sources. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the value market. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Business, Factiva, and D&B Hoovers), white papers, annual reports, companies house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the IVD Quality Control market. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include CEOs, consultants, subject-matter experts, directors, general managers, developers, and other key opinion leaders of the various companies that offer IVD Quality Control products. Primary sources from the demand side include industry experts such as hospital directors, infection control practitioners, technicians, and other medical professionals.

Primary research was conducted to identify segmentation types; industry trends; technology trends; key players; and key market dynamics such as drivers, restraints, opportunities, challenges, and key player strategies.

A breakdown of the primary respondents is provided below:

In Vitro Diagnostics (IVD) Quality Control Market Size, and Share

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2020: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the IVD quality control market was arrived at after data triangulation from different approaches. After each approach, the weighted average of all approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Approach to derive the market size and estimate market growth

The market rankings for leading players were ascertained after a detailed assessment of their revenues from the IVD Quality Control business using secondary data available through paid and unpaid sources. Owing to data limitations, in certain cases, the revenue share was arrived at after a detailed assessment of the product portfolios of major companies and their respective sales performance. At each point, this data was validated through primary interviews with industry experts.

Objectives of the Study

  • To validate the segmentation defined through the assessment of the product portfolios of the leading players in the market
  • To understand key industry trends and issues defining the growth objectives of market players
  • To gather both demand- and supply-side validation of the key factors affecting market growth, including market drivers, restraints, opportunities, and challenges
  • To validate assumptions for the market sizing and forecasting model used for this market study
  • To understand the market positions of the leading players in the IVD quality control market and their shares/rankings

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the RoE IVD quality control market includes Switzerland, the Netherlands, and others.
  • Further breakdown of the Southeast Asia IVD quality control market includes Singapore, New Zealand, and others

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 4180
Published ON
Feb, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the In Vitro Diagnostics (IVD) Quality Control Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback